An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups

Murray Baron, Bashar Kahaleh, Elana J Bernstein, Lorinda Chung, Philip J Clements, Christopher Denton, Robyn T Domsic, Nava Ferdowsi, Ivan Foeldvari, Tracy Frech, Jessica K Gordon, Marie Hudson, Sindhu R Johnson, Dinesh Khanna, Zsuzsannah McMahan, Peter A Merkel, Sonali Narain, Mandana Nikpour, John D Pauling, Laura Ross & 2 others Antonia Maria Valenzuela Vergara, Alessandra Vacca

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The Scleroderma Clinical Trials Consortium represents many of the clinical researchers in the world who are interested in improving the efficiency of clinical trials in systemic sclerosis. The Scleroderma Clinical Trials Consortium has established 11 working groups to develop and validate better ways of measuring and recording multiple aspects of this heterogeneous disease. These include groups working on arthritis, disease damage, disease activity, cardiac disease, juvenile systemic sclerosis, the gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung disease, and skin measurement. Members of the Scleroderma Clinical Trials Consortium may join any one or more of these groups. Some of the working groups have only recently started their work, some are nearing completion of their mandated tasks, and others are in the midst of their projects. All these projects, which are described in this article, will help improve clinical trials and observational studies by improving or developing better, more sensitive ways of measuring various aspects of the disease. As Lord Kelvin stated, “To measure is to know. If you cannot measure it you cannot improve it.” The Scleroderma Clinical Trials Consortium is dedicated to improving the lives of patients with systemic sclerosis and it is our hope that the contributions of the working groups will be one important step in this process.

Original languageEnglish
Pages (from-to)17-27
Number of pages11
JournalJournal of Scleroderma and Related Disorders
Volume4
Issue number1
Early online date18 Jul 2018
DOIs
Publication statusE-pub ahead of print - 18 Jul 2018

Keywords

  • Arthritis
  • Gastrointestinal
  • Interstitial lung disease
  • Myocardial
  • Systemic sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Baron, M., Kahaleh, B., Bernstein, E. J., Chung, L., Clements, P. J., Denton, C., ... Vacca, A. (2018). An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. Journal of Scleroderma and Related Disorders, 4(1), 17-27. https://doi.org/10.1177/2397198318783926

An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. / Baron, Murray; Kahaleh, Bashar; Bernstein, Elana J; Chung, Lorinda; Clements, Philip J; Denton, Christopher; Domsic, Robyn T; Ferdowsi, Nava; Foeldvari, Ivan; Frech, Tracy; Gordon, Jessica K; Hudson, Marie; Johnson, Sindhu R; Khanna, Dinesh; McMahan, Zsuzsannah; Merkel, Peter A; Narain, Sonali; Nikpour, Mandana; Pauling, John D; Ross, Laura; Valenzuela Vergara, Antonia Maria; Vacca, Alessandra.

In: Journal of Scleroderma and Related Disorders, Vol. 4, No. 1, 18.07.2018, p. 17-27.

Research output: Contribution to journalArticle

Baron, M, Kahaleh, B, Bernstein, EJ, Chung, L, Clements, PJ, Denton, C, Domsic, RT, Ferdowsi, N, Foeldvari, I, Frech, T, Gordon, JK, Hudson, M, Johnson, SR, Khanna, D, McMahan, Z, Merkel, PA, Narain, S, Nikpour, M, Pauling, JD, Ross, L, Valenzuela Vergara, AM & Vacca, A 2018, 'An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups', Journal of Scleroderma and Related Disorders, vol. 4, no. 1, pp. 17-27. https://doi.org/10.1177/2397198318783926
Baron, Murray ; Kahaleh, Bashar ; Bernstein, Elana J ; Chung, Lorinda ; Clements, Philip J ; Denton, Christopher ; Domsic, Robyn T ; Ferdowsi, Nava ; Foeldvari, Ivan ; Frech, Tracy ; Gordon, Jessica K ; Hudson, Marie ; Johnson, Sindhu R ; Khanna, Dinesh ; McMahan, Zsuzsannah ; Merkel, Peter A ; Narain, Sonali ; Nikpour, Mandana ; Pauling, John D ; Ross, Laura ; Valenzuela Vergara, Antonia Maria ; Vacca, Alessandra. / An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. In: Journal of Scleroderma and Related Disorders. 2018 ; Vol. 4, No. 1. pp. 17-27.
@article{c2a741d9644745f394a6579419593d7a,
title = "An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups",
abstract = "The Scleroderma Clinical Trials Consortium represents many of the clinical researchers in the world who are interested in improving the efficiency of clinical trials in systemic sclerosis. The Scleroderma Clinical Trials Consortium has established 11 working groups to develop and validate better ways of measuring and recording multiple aspects of this heterogeneous disease. These include groups working on arthritis, disease damage, disease activity, cardiac disease, juvenile systemic sclerosis, the gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung disease, and skin measurement. Members of the Scleroderma Clinical Trials Consortium may join any one or more of these groups. Some of the working groups have only recently started their work, some are nearing completion of their mandated tasks, and others are in the midst of their projects. All these projects, which are described in this article, will help improve clinical trials and observational studies by improving or developing better, more sensitive ways of measuring various aspects of the disease. As Lord Kelvin stated, “To measure is to know. If you cannot measure it you cannot improve it.” The Scleroderma Clinical Trials Consortium is dedicated to improving the lives of patients with systemic sclerosis and it is our hope that the contributions of the working groups will be one important step in this process.",
keywords = "Arthritis, Gastrointestinal, Interstitial lung disease, Myocardial, Systemic sclerosis",
author = "Murray Baron and Bashar Kahaleh and Bernstein, {Elana J} and Lorinda Chung and Clements, {Philip J} and Christopher Denton and Domsic, {Robyn T} and Nava Ferdowsi and Ivan Foeldvari and Tracy Frech and Gordon, {Jessica K} and Marie Hudson and Johnson, {Sindhu R} and Dinesh Khanna and Zsuzsannah McMahan and Merkel, {Peter A} and Sonali Narain and Mandana Nikpour and Pauling, {John D} and Laura Ross and {Valenzuela Vergara}, {Antonia Maria} and Alessandra Vacca",
year = "2018",
month = "7",
day = "18",
doi = "10.1177/2397198318783926",
language = "English",
volume = "4",
pages = "17--27",
journal = "Journal of Scleroderma and Related Disorders",
issn = "2397-1983",
publisher = "Sage Publications",
number = "1",

}

TY - JOUR

T1 - An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups

AU - Baron, Murray

AU - Kahaleh, Bashar

AU - Bernstein, Elana J

AU - Chung, Lorinda

AU - Clements, Philip J

AU - Denton, Christopher

AU - Domsic, Robyn T

AU - Ferdowsi, Nava

AU - Foeldvari, Ivan

AU - Frech, Tracy

AU - Gordon, Jessica K

AU - Hudson, Marie

AU - Johnson, Sindhu R

AU - Khanna, Dinesh

AU - McMahan, Zsuzsannah

AU - Merkel, Peter A

AU - Narain, Sonali

AU - Nikpour, Mandana

AU - Pauling, John D

AU - Ross, Laura

AU - Valenzuela Vergara, Antonia Maria

AU - Vacca, Alessandra

PY - 2018/7/18

Y1 - 2018/7/18

N2 - The Scleroderma Clinical Trials Consortium represents many of the clinical researchers in the world who are interested in improving the efficiency of clinical trials in systemic sclerosis. The Scleroderma Clinical Trials Consortium has established 11 working groups to develop and validate better ways of measuring and recording multiple aspects of this heterogeneous disease. These include groups working on arthritis, disease damage, disease activity, cardiac disease, juvenile systemic sclerosis, the gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung disease, and skin measurement. Members of the Scleroderma Clinical Trials Consortium may join any one or more of these groups. Some of the working groups have only recently started their work, some are nearing completion of their mandated tasks, and others are in the midst of their projects. All these projects, which are described in this article, will help improve clinical trials and observational studies by improving or developing better, more sensitive ways of measuring various aspects of the disease. As Lord Kelvin stated, “To measure is to know. If you cannot measure it you cannot improve it.” The Scleroderma Clinical Trials Consortium is dedicated to improving the lives of patients with systemic sclerosis and it is our hope that the contributions of the working groups will be one important step in this process.

AB - The Scleroderma Clinical Trials Consortium represents many of the clinical researchers in the world who are interested in improving the efficiency of clinical trials in systemic sclerosis. The Scleroderma Clinical Trials Consortium has established 11 working groups to develop and validate better ways of measuring and recording multiple aspects of this heterogeneous disease. These include groups working on arthritis, disease damage, disease activity, cardiac disease, juvenile systemic sclerosis, the gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung disease, and skin measurement. Members of the Scleroderma Clinical Trials Consortium may join any one or more of these groups. Some of the working groups have only recently started their work, some are nearing completion of their mandated tasks, and others are in the midst of their projects. All these projects, which are described in this article, will help improve clinical trials and observational studies by improving or developing better, more sensitive ways of measuring various aspects of the disease. As Lord Kelvin stated, “To measure is to know. If you cannot measure it you cannot improve it.” The Scleroderma Clinical Trials Consortium is dedicated to improving the lives of patients with systemic sclerosis and it is our hope that the contributions of the working groups will be one important step in this process.

KW - Arthritis

KW - Gastrointestinal

KW - Interstitial lung disease

KW - Myocardial

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85062745310&partnerID=8YFLogxK

U2 - 10.1177/2397198318783926

DO - 10.1177/2397198318783926

M3 - Article

VL - 4

SP - 17

EP - 27

JO - Journal of Scleroderma and Related Disorders

JF - Journal of Scleroderma and Related Disorders

SN - 2397-1983

IS - 1

ER -